Takeover interest in migraine-treatment company Biohaven Pharmaceuticals (NYSE: BHVN) is said to be “robust” as the company explores a sale ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE